HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Dietary Supplement Industry In 2023: Little New Expected In NDI Notification Enforcement

Executive Summary

Chief executives of OTC drug and supplement industry trade groups discussed potential market and regulatory developments affecting their members’ businesses. HBW Insight concludes series here reporting on supplement sector’s outlook for FDA potentially resolving its protracted struggle with NDI notification requirement.

You may also be interested in...



US Supplement Industry To Enjoy Recognition Week Under Resolution Lee, Sinema Propose In Senate

Senate recognizes “dietary supplements have become a routine part of the lives of millions of individuals in the United States” and “the contributions of the natural product industry to the workforce and economy,” says ‘‘Natural Product Industry Week’’ resolution proposed by Sens. Mike Lee and Kyrsten Sinema.

US FDA Allows Supplement Firms More Time To Submit NDI Notifications, And For It To Respond

More time for notifications than current deadline of at least 75 days before NDI-containing product is offered for sale in US doesn’t solve problems with FDA’s management of NDI regulation, say trade groups.

NDI Notification Guidance Deadline Included In Senate Draft Bill For FDA User Fee Programs

HELP Committee Chairwoman Patty Murray, and ranking member Richard Burr also include supplement registration requirement in discussion draft for reauthorizing FDA’s user fee programs for prescription, generic and biosimilar drugs and medical devices.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153319

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel